{"id":3907,"date":"2026-10-26T09:00:00","date_gmt":"2026-10-26T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3907"},"modified":"2026-10-26T19:30:33","modified_gmt":"2026-10-26T23:30:33","slug":"sanovo-tests-early-egfr-and-met-dual-blockade","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3907","title":{"rendered":"SANOVO Tests Early EGFR and MET Dual Blockade"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

HUTCHMED; AstraZeneca<\/p>\n

Event Type<\/strong><\/p>\n

Phase 3 detailed data<\/p>\n

Modality<\/strong><\/p>\n

Oral MET inhibitor plus EGFR inhibitor<\/p>\n

Asset<\/strong><\/p>\n

Savolitinib plus osimertinib<\/p>\n

Target<\/strong><\/p>\n

MET; EGFR<\/p>\n

Disease Area<\/strong><\/p>\n

Untreated EGFR-mutant, MET-overexpressing advanced NSCLC<\/p>\n

Summary<\/h4>\n

New Phase III data presented on 26 October show a large progression-free survival benefit from savolitinib plus osimertinib over osimertinib alone in untreated EGFR-mutant, MET-overexpressing advanced NSCLC in China. Overall-survival findings are promising but require scrutiny of the prespecified testing plan.<\/p>\n

SANOVO randomized 326 patients, 162 to the combination and 164 to placebo plus osimertinib. In the IHC 2+\/3+ intention-to-treat group, blinded-review median PFS was 24.9 versus 13.8 months (HR 0.56, 95% CI 0.43\u20130.74; P<0.0001). In the high-MET subset, median PFS was 24.8 versus 11.1 months (HR 0.45, 95% CI 0.31\u20130.66). The reported OS HR was 0.48 (95% CI 0.33\u20130.68), with medians 44.5 and 34.9 months; 49 versus 83 deaths had occurred. Adverse-event discontinuation on combination was 14.8%; fatal adverse events excluding progression were 4.3% versus 4.8%. The PFS cutoff was 31 July 2026. This disclosure adds quantitative data to the August top-line result.<\/p>\n

Deep Analysis<\/h4>\n

Randomization against active first-line osimertinib and biomarker selection make the PFS signal compelling within the Chinese trial. A roughly 11-month absolute median PFS gain in the overall selected group is materially larger than many add-on kinase strategies. Yet the high-MET subset and broader IHC 2+\/3+ group must not be conflated. The release does not establish how OS multiplicity was controlled, nor does it provide full grade-specific toxicity, dose-intensity or post-progression treatment tables. First-line MET overexpression may reflect intrinsic bypass biology, but assay cutoffs, sample timing and geographic prevalence determine who would qualify elsewhere. SANOVO is domestic-only evidence. It complements the global post-osimertinib SAFFRON trial, reported separately on 25 October, but does not establish the same effect in a global first-line population. HUTCHMED plans a China supplemental application; filing is not approval.<\/p>\n

Company and Product Background<\/h4>\n

HUTCHMED discovered savolitinib, an oral MET kinase inhibitor, and develops it with AstraZeneca. Osimertinib inhibits mutant EGFR. MET overexpression can provide bypass signaling in EGFR-mutant non-small-cell lung cancer. The study enrolled EGFR exon-19 deletion or L858R disease with MET expression defined by immunohistochemistry.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> concurrent MET inhibition prevents or delays EGFR bypass resistance; randomized PFS and OS point estimates support it.<\/li>\n
  • Interpretation B:<\/strong> benefit is concentrated in a stringent high-MET subset or influenced by care after progression; incomplete assay and downstream-treatment detail leaves this open.<\/li>\n
  • Upgrade:<\/strong> full statistical hierarchy, mature OS, safety and quality-of-life tables, centrally reproducible IHC, and multinational validation. Downgrade:<\/strong> smaller benefit outside China or cumulative hepatic and edema toxicity. Falsification:<\/strong> a biomarker-matched global trial finds no clinically meaningful benefit.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: SANOVO makes first-line EGFR\u2013MET dual blockade a strong China-specific precision-oncology candidate. The size of the OS signal should remain provisional until its testing framework and full dataset are public.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: positive for PFS; OS uncertain. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    New Phase III data presented on 26 October show a large progression-free survival benefit from savolitinib plus osimertinib over osimertinib alone in untreated EGFR-mutant, MET-overexpressing advanced NSCLC in China. Overall-survival findings are promising but…<\/p>\n","protected":false},"author":1,"featured_media":3916,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1215,471,357,1107,1219],"class_list":["post-3907","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-egfr-mutant-nsclc","tag-hutchmed","tag-osimertinib","tag-phase-3","tag-savolitinib"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3907"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3907\/revisions"}],"predecessor-version":[{"id":3923,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3907\/revisions\/3923"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3916"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}